Abstract
Schistosomiasis affects over 250 million people, predominantly in Sub-Saharan Africa. In Schistosoma-endemic regions a lack of natural sterilizing immunity means individuals are repeatedly infected, treated and reinfected. Due to difficulties in tracking infection in endemic areas, the kinetics of the host immune response during these reinfections have not been elucidated. Here, we use repeated (3x) controlled human Schistosoma mansoni (Sm) infection (repeated CHI) to directly study how antigen-specific T cells develop during reinfection. We compared these responses to natural Sm-infected endemic Ugandan individuals. We report that a mixed Th1/Th2/regulatory CD4+ T cell response develops in repeated CHI, primarily against adult worm antigens. Adult worm-specific responses after repeated CHI were similar to those observed in naturally infected endemic participants. However, endemic participants showed differential responses to antigens from the egg and cercariae life-cycle stages. Repeated CHI (3x) with sequential exposure to Sm cercariae of different sexes (male-female-male) revealed an elevated CD4+ T cell cytokine response to adult worm and egg antigens. Our findings demonstrate that reinfection with single-sex schistosomes elicits adult worm-specific T cell cytokine responses that reflect endemic-natural infection, highlighting the translatability of the CHI model to natural infection in endemic settings. Overall, this study advances our understanding of how schistosome immune responses develop over reinfection cycles in the human host, thereby increasing our understanding of the immunology of natural schistosome (re)infection.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT05085470
Funding Statement
This research received funding from the European Union. Part of the work was conducted at the MRC/UVRI and LSHTM Uganda Research Unit which is jointly funded by the UK Medical Research Council part of UK Research and Innovation and the UK Foreign, Commonwealth and Development Office.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study received ethical approval from De Medical Ethics Committee Leiden The Hague Delft, Netherlands. Part of the work on endemic setting received ethical approval from the Ugandan Virus Research Institue Research Ethics committee and regulatory approval was obtained from the Ugandan National Council for Science and Technology
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript. Additional data is available upon reasonable request to the author.
